In vivo pharmacology

Comprehensive panel of models and readouts for different therapeutic areas

NovAliX provides considerable in vivo pharmacology resources encompassing key therapeutic areas: oncology, immuno-inflammation, infectious diseases, fibrosis, kidney diseases, osteoarthritis, metabolic disorders.

Both stand-alone and integrated drug discovery projects, from target validation to the selection of the final clinical candidate, are supported.

The in vivo pharmacology study design elements for assessing novel drug potential includes:

  • Longitudinal disease progression pharmacology readouts
  • Biobank samples of kinetic studies for main preclinical models—target validation
  • Clinical endpoints readouts and quantitative histology analysis
  • Target engagement and receptor occupancy
  • Tissue biomarkers: gene and protein expression analysis for disease-specific panels (immunoassay, immunophenotyping, RT-PCR, immunohistochemistry, in situ hybridization, etc.)
  • State-of-the-art in vivo imaging: X-ray computed tomography, bioluminescence and fluorescence imaging, echography imaging
  • Steady state pharmacokinetics

The pathophysiology models are validated with appropriate standard-of-care drugs and robust statistical analyses.


Liquid and solid tumorsCell line derived xenograft models (CDX)
Bladder (RT-112)
Liver (HuH-7)
Lung (A549, NCI-H1299, NCI-H1975)
Leukemia (MOLM-13)
Lymphoma (Raji-Luc)
Pancreas (BxPC-3)
Stomach (NUGC-3, SNU-16)
Solid tumorsSyngeneic models
Colon (MC38)
Orthotopic tumorsMetastasis models
Liver metastasis
Brain metastasis


Immune function studiesTDAR (T-Cell-Dependent Antibody Response)
TIDAR (T-Cell-Independent Antibody Response)
B cells depletion
Acute models
– General inflammation (LPS, Zymosan, anti-CD3, CpG)
– Dermal inflammation (air pouch, IL-23)
– Respiratory (intranasal LPS) or any other trigger
Inflammatory Bowel DiseaseDSS (acute & chronic)
DSS-induced colon strictures/fibrosis
Mdr1a-/- model
T Cell Adoptive Transfer Model
Rheumatoid ArthritisCollagen antibody-induced arthritis (CAIA)
Collagen-induced arthritis (CIA)
K/BxN serum transfer-induced arthritis
Skin DiseasesImiquimod-induced psoriasis
Contact dermatitis (DNFB)
Calcipotriol-induced atopic dermatitis
IL33-induced atopic dermatitis
Systemic lupus erythematosusMRL/lpr model of spontaneous SLE
Imiquimod-induced lupus
Psoriatic arthritisIL-23 induced model

Infectious diseases

Lung infectionLung infection mouse model induced by Mycobacterium abscessus
Lung infection mouse model induced by Mycobacterium avium


Liver fibrosisCarbon tetrachloride (CCl4)
Choline deficient high fat diet (CDHFD; NASH)
Colon fibrosis (Crohn’s disease)DSS-induced colon strictures/fibrosis
Lung fibrosisRadiation-induced lung fibrosis
Kidney fibrosisUnilateral ureteral obstruction (UUO)

Kidney diseases

Acute kidney injuryIschemia reperfusion kidney injury (IRI)
Sepsis-associated-AKI (LPS)
Chronic kidney diseaseAdenine-induced nephropathy with mineral bone disorders (CKD-MBD)
DOCA-salt and unilateral nephrectomy (Focal Segmental Glomerulosclerosis)
Unilateral ureteral obstruction (UUO; kidney fibrosis)
MRL/lpr model of lupus nephritis (SLE)
Polycystic kidney disease (PCKD)


Post-traumatic osteoarthritisRat meniscectomy (surgically induced)

Metabolic disorders

Type 1 diabetesAkita (spontaneous type 1 diabetes Ins2 mutation)
Type 2 diabetesZDF rat model
LepRdb/dbmouse model
Metabolic syndromeWestern diet-induced
ObesityLepob/obmouse model

We are committed to advancing in vivo models and investigating endpoints for translation to clinical settings, coupled with pharmacokinetic assessments to measure drug exposure levels.

Want more information?

We are ready to support your projects